Sanofi $SNY Shares Bought by American Century Companies Inc.

American Century Companies Inc. lifted its stake in shares of Sanofi (NASDAQ:SNY) by 29.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,959,185 shares of the company’s stock after buying an additional 443,941 shares during the quarter. American Century Companies Inc. owned approximately 0.08% of Sanofi worth $94,648,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Sanofi in the first quarter valued at $177,831,000. Federated Hermes Inc. increased its position in shares of Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after purchasing an additional 1,456,269 shares during the last quarter. OLD Mission Capital LLC acquired a new stake in shares of Sanofi in the 1st quarter valued at about $48,938,000. Regal Partners Ltd raised its stake in shares of Sanofi by 102.3% in the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock valued at $74,794,000 after purchasing an additional 782,838 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in shares of Sanofi by 15.1% during the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock worth $179,914,000 after purchasing an additional 425,597 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Sanofi in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Stock Up 2.3%

NASDAQ:SNY opened at $50.28 on Wednesday. The firm has a market capitalization of $123.46 billion, a PE ratio of 11.78, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. The stock has a 50 day moving average of $49.41 and a 200-day moving average of $49.25. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter last year, the business posted $2.25 EPS. The business’s revenue was down 7.5% on a year-over-year basis. Analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.